Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data

Autor: van der Ploeg, C. P B, van den Akker-van Marle, M. E., Vernooij-van Langen, A. M M, Elvers, L. H., Gille, J. J P, Verkerk, P. H., Dankert-Roelse, J. E., Loeber, J. G., Triepels, R. H., Van der Ploeg, C. P B, van der Pal, S. M., Dompeling, E., Pals, G., van den Akker van Marle, M. E., Gulmans, V. A M, Oey-Spauwen, M. J W, Wijnands, Y. H H M, Castricum, L. M., Arets, H. G M, van der Ent, C. K., Tiddens, H. A W M, de Rijke, Y. B., Yntema, J. B.

Publikováno v: Journal of Cystic Fibrosis, 14(2), 194-202
van der Ploeg, C P B, van den Akker-v Marie, ME, Vernooij-van Langen, A M M, Elvers, L H, Gille, J J P, Verkerk, P H & Dankert-Roelse, J E 2015, ' Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data ', Journal of Cystic Fibrosis, vol. 14, no. 2, pp. 194-202 . https://doi.org/10.1016/j.jcf.2014.08.007
Journal of Cystic Fibrosis, 14(2), 194. Elsevier
Journal of Cystic Fibrosis, 14(2), 194-202. Elsevier Science
Journal of Cystic Fibrosis, 14(2), 194-202. Elsevier

Background: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. Methods: We used primary data to comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cbac0fa3ee8eb5c4763af31dde60ea
http://hdl.handle.net/1887/108027